Jade Biosciences, Inc. Common Stock (JBIO) is a publicly traded Healthcare sector company. As of July 9, 2026, JBIO trades at $22.45 with a market cap of $1.37B and a P/E ratio of -7.14. JBIO moved -0.44% today. Year to date, JBIO is +46.01%; over the trailing twelve months it is +114.98%. Its 52-week range spans $6.57 to $28.00. Analyst consensus is strong buy with an average price target of $48.50. Rallies surfaces JBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for JBIO combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $22.45 |
| Market Cap | $1.37B |
| P/E Ratio | -7.14 |
| EPS | $-3.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.00 |
| 52-Week Low | $6.57 |
| Volume | 207.63K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-127.41M |
| Gross Margin | 0.00% |
10 analysts cover JBIO: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $48.50.